Kairos Pharma Receives DoD Grant to Advance Lung Cancer Biomarker Research
Kairos Pharma secures a Department of Defense grant to support its innovative cancer research, focusing on developing ENV105, a potential breakthrough in addressing drug resistance in prostate and lung cancers.
Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has received a Department of Defense grant to advance its lung cancer biomarker research. The company is currently developing ENV105, an antibody targeting CD105, a protein critical in understanding and potentially overcoming cancer treatment resistance.
The research focuses on two key clinical trials for ENV105 in prostate and EGFR-dependent non-small cell lung cancers. Safety and interim efficacy results are expected in the second quarter of 2025. By targeting CD105, which drives resistance to various cancer treatments, ENV105 aims to restore the effectiveness of standard therapies across multiple cancer types.
The grant represents a significant milestone for Kairos Pharma, providing non-dilutive funding to support its innovative research. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing critical unmet medical needs in oncology.
With ongoing support from analyst firms like EF Hutton and HC Wainwright, and a robust intellectual property portfolio extending into the 2030s, Kairos Pharma is positioning itself as a potential leader in developing novel cancer therapeutics that combat treatment resistance.